Indivior Pharmaceuticals PE ratio INDV
Share price divided by earnings per share over the last twelve months, since 2025.
- Today, Nov 2, 2026
- 10.2×
- Peer median
- 31.4×
Indivior Pharmaceuticals' PE ratio is 10.2× as of Nov 2, 2026: a share price of $36.28 against $3.57 of earnings per share over the last twelve months.
The median for 10 large drugmakers of a similar size is 31.4×.
PE ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 10.2× | 9.9× | 35.0× |
| 2025 | 35.5× | 28.8× | 35.5× |
Against its peers
Companies in Drug Manufacturers - General nearest Indivior Pharmaceuticals' size, closest first, today.
| Company | PE ratio |
|---|---|
| INDVIndivior Pharmaceuticals | 10.2× |
| ARQTArcutis Biotherapeutics | 142× |
| LQDALiquidia | 30.1× |
| OGNOrganon | 18.2× |
| LGNDLigand Pharmaceuticals | 32.7× |
| AMRXAmneal Pharmaceuticals | 41.7× |
| NRIXNurix Therapeutics | 11.1× |
| KNSAKiniksa Pharmaceuticals International | 93.6× |
| ALKSAlkermes plc. | 118× |
| PBHPrestige Consumer Healthcare | 13.9× |
| HRMYHarmony Biosciences | 12.3× |
| Peer median | 31.4× |
Where Indivior Pharmaceuticals ranks
What the PE ratio tells you
Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.
Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.
More on Indivior Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.